ClinicalTrials.gg
Not yet recruitingNCT07685041Updated Jul 6, 2026

An Open-label, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HS-10504 on the Pharmacokinetics of Midazolam in Patients With Non-small Cell Lung Cancer

A Phase 1 interventional study of HS-10504; midazolam in NSCLC, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, fixed-sequence Phase I clinical trial to evaluate the effect of HS-10504 on the pharmacokinetics of midazolam (CYP3A4 substrate) in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after treatment with EGFR-TKIs.

Read the detailed description

This study consists of two stages: Stage 1 (DDI evaluation period, C0D1 to C2D21) and Stage 2 (drug donation period, from C3D1 onward). Each cycle contains 21 days, except for Cycle 0.

Stage 1 (DDI evaluation period, C0D1 to C2D21): Enrolled participants receive a single oral dose of midazolam oral solution 1 mg (2 mg/mL, 0.5 mL) on C0D1 and C2D20, respectively; and receive HS-10504 tablets 400 mg (100 mg/tablet, 4 tablets) once daily from C1D1 to C2D21.

Stage 2 (drug donation period, from C3D1 onward): After completing Stage 1, participants may decide, based on the investigator's judgment and their own willingness, whether to enter Stage 2 (the extended drug donation period, which is optional and not mandatory). This stage continues until the participant voluntarily requests discontinuation, is lost to follow-up, experiences disease progression, develops intolerable toxicity, is judged by the investigator to no longer derive benefit from the treatment, or the drug has been approved for marketing, whichever occurs first.

02

Conditions studied

  • NSCLC

Keywords

  • Phase I
  • Drug interaction
  • HS-10504
  • NSCLC
03

In context

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed locally advanced or NSCLC
  2. Disease progression or intolerance to prior third-generation EGFR TKI therapy in patients with mNSCLC
  3. Confirmed EGFR mutation positivity in participants before enrollment.
  4. At least one target lesion according to 1.1
  5. (ECOG) performance status (PS) 0-1 with no deterioration in the 2 weeks prior to the first dose
  6. Minimum greater than 12 weeks
  7. Female participants of must agree to use appropriate (refer to section 12.5) from the time of signing until 6 months after the last dose, and should not breastfeed; male participants must agree to use barrier contraception (i.e., condoms) from the time of signing informed consent until 6 months after the last dose
  8. Willing to participate in this clinical trial, understand the study procedures, and be able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Has received or is currently receiving the following treatments:

    1. Prior or current treatment with a fourth-generation EGFR tyrosine kinase inhibitor.
    2. Use of strong/moderate inhibitors or strong/moderate inducers of , CYP3A5, CYP2C8, and/or CYP2D6, or narrow therapeutic index drugs that are sensitive substrates of CYP3A4, CYP3A5, P-gp, and BCRP within 14 days or 5 half-lives (whichever is longer) prior to the first dose of product; or need to continue these medications during the study period.
    3. Use of drugs that affect gastric acid secretion or intragastric pH within 7 days prior to the first dose of investigational product.
    4. Currently receiving treatment with drugs known to prolong the or that may cause torsade de pointes; or need to continue these medications during the study period
  2. Presence of toxicities from prior anti-tumor therapy that have not resolved to \< Grade 2 according to the (CTCAE) version 5.0.
  3. History of other primary .
  4. Inadequate bone marrow reserve or hepatic/renal organ function.
  5. Meets any of the following cardiac criteria:

    1. Mean Fridericia-corrected QT interval (QTcF) > 470 msec on resting (ECG);
    2. Resting ECG shows any rhythm, conduction, or ECG morphological abnormality deemed important by the investigator (e.g., complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, and PR interval > 250 msec, etc.);
    3. Presence of any factors that increase the risk of QT prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, unexplained sudden death in a first-degree relative under 40 years of age, or any concomitant medication that prolongs the QT interval;
    4. (LVEF) \< 50%.
  6. Severe, uncontrolled, or active cardiovascular disease.
  7. Severe or poorly controlled diabetes mellitus.
  8. Severe or poorly controlled hypertension.
  9. Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose.
  10. Severe arterial thrombotic event within 3 months prior to the first dose.
  11. Severe infection within 4 weeks prior to the first dose.
  12. Continuous therapy for more than 30 days within 30 days prior to the first dose, or need for long-term corticosteroid therapy, or other acquired or congenital immunodeficiency diseases, or history of organ transplantation
  13. Known active infectious disease.
  14. Clinically severe gastrointestinal abnormalities that may affect drug intake, transport, or absorption.
  15. Hepatic encephalopathy, hepatorenal syndrome, or ≥C (incomplete in original).
  16. Other moderate to severe pulmonary diseases that seriously impair respiratory function and may interfere with the detection or management of drug-related pulmonary toxicity.
  17. Previous history of severe neurological or psychiatric disorders.
  18. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  19. History of severe allergies, or to any component of HS-10504 tablets or midazolam oral solution, or history of hypersensitivity to drugs with a similar chemical structure or of the same class as HS-10504.
  20. History of ventilation difficulty or severe airway obstruction.
  21. Any severe or uncontrolled ocular condition that, in the physician's judgment, may increase the patient's risk; or ocular abnormalities requiring surgery or expected to require surgical treatment during the study period.
  22. Participants who, in the investigator's judgment, may have poor compliance with study procedures and requirements.
  23. In the investigator's judgment, presence of any life-threatening complication.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Drug-drug interaction Arm

    Drug: HS-10504; midazolam

Interventions

  • DrugHS-10504; midazolam

    HS-10504:Participants receive HS-10504 tablets 400 mg (100 mg/tablet, 4 tablets) once daily Midazolam:Participants receive a single oral dose of midazolam oral solution 1 mg (2 mg/mL, 0.5 mL) on C0D1 and C2D20, respectively。

06

What researchers measure

Primary outcomes

  1. Evaluation of PK parameters of Midazolam: Cmax

    To evaluate the Cmax of Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  2. Evaluation of PK parameters of Midazolam: AUC0-t

    To evaluate the AUC0-t of Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  3. Evaluation of PK parameters of Midazolam: AUC0-∞

    To evaluate the AUC0-∞ of Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

Secondary outcomes

  1. Evaluation of PK parameters of Midazolam: Tmax

    To evaluate the Tmax of Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  2. Evaluation of PK parameters of Midazolam: t1/2z

    To evaluate the t1/2z of Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  3. Evaluation of PK parameters of Midazolam: λz

    To evaluate the λz of Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  4. Evaluation of PK parameters of Midazolam: CLz/F

    To evaluate the CLz/F of Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  5. Evaluation of PK parameters of Midazolam: Vz/F.

    To evaluate the Vz/F of Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  6. Evaluation of PK parameters of 1-OH Midazolam: Cmax

    To evaluate the Cmax of 1-OH Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  7. Evaluation of PK parameters of 1-OH Midazolam: AUC0-t

    To evaluate the AUC0-t of 1-OH Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  8. Evaluation of PK parameters of 1-OH Midazolam: AUC0-∞

    To evaluate the AUC0-∞ of 1-OH Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  9. Evaluation of PK parameters of 1-OH Midazolam: Tmax

    To evaluate the Tmax of 1-OH Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  10. Evaluation of PK parameters of 1-OH Midazolam: t1/2z.

    To evaluate the t1/2z of 1-OH Midazolam administered alone and in combination with HS-10504

    Time frame: 24 hours after administration of Midazolam

  11. Evaluation of PK parameters of HS-10504 and metabolite M6-2: Cmin

    To evaluate the Cmin of HS-10504 and metabolite M6-2

    Time frame: 24 hours after administration of HS-10504

  12. Evaluation of PK parameters of HS-10504 and metabolite M6-2: Cmax

    To evaluate the Cmax of HS-10504 and metabolite M6-2

    Time frame: 24 hours after administration of HS-10504

  13. Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-24 h

    To evaluate the AUC0-24 h of HS-10504 and metabolite M6-2

    Time frame: 24 hours after administration of HS-10504

  14. Evaluation of PK parameters of HS-10504 and metabolite M6-2: Tmax.

    To evaluate the Tmax of HS-10504 and metabolite M6-2

    Time frame: 24 hours after administration of HS-10504

  15. Adverse events

    To evaluate the adverse events (AEs) of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  16. blood pressure

    To evaluate the blood pressure of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  17. Pulse

    To evaluate the Puls of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  18. body temperature

    To evaluate the body temperature of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  19. respiratory rate

    To evaluate the respiratory rate of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  20. complete blood count (CBC)

    To evaluate the complete blood count (CBC) of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  21. urinalysis

    To evaluate the urinalysis of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  22. blood chemistry

    To evaluate the blood chemistry of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  23. coagulation tests

    To evaluate the coagulation tests of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

  24. 12-lead electrocardiogram(heart rate)

    To evaluate the 12-lead electrocardiogram(heart rate) of Midazolam administered alone and in combination with HS-10504

    Time frame: through study completion, an average of 43 days

  25. 12-lead electrocardiogram(PR)

    To evaluate the 12-lead electrocardiogram(PR) of Midazolam administered alone and in combination with HS-10504

    Time frame: through study completion, an average of 43 days

  26. 12-lead electrocardiogram(RR)

    To evaluate the 12-lead electrocardiogram(RR) of Midazolam administered alone and in combination with HS-10504

    Time frame: through study completion, an average of 43 days

  27. 12-lead electrocardiogram(QRS duration)

    To evaluate the 12-lead electrocardiogram(QRS duration) of Midazolam administered alone and in combination with HS-10504

    Time frame: through study completion, an average of 43 days

  28. 12-lead electrocardiogram(QTcF)

    To evaluate the 12-lead electrocardiogram(QTcF) of Midazolam administered alone and in combination with HS-10504

    Time frame: through study completion, an average of 43 days

  29. physical examination of Midazolam administered alone and in combination with HS-10504.

    To evaluate the abnormal of the physical examination(1) Eyes; 2) Ear, nose, throat; 3) Cardiovascular system; 4) Chest and respiratory system; 5) Abdominal examination; 6) Skin and mucous membranes; 7) Spine and limbs; 8) Musculoskeletal system; 9) Nervous system; 10) Lymph nodes; 11) Genitourinary system; 12) Others.) of Midazolam administered alone and in combination with HS-10504.

    Time frame: through study completion, an average of 43 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Nov 2026, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jul 6, 2026
StartEst.
Jun 27, 2026
Primary completionEst.
Nov 19, 2026
CompletionEst.
Jul 20, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07685041
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Jun 27, 2026 (estimated)
Primary completion
Nov 19, 2026 (estimated)
Completion
Jul 20, 2027 (estimated)
Last update
Jul 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion